Colon cancer clinical practice guidelines

Paul F. Engstrom, Al B. Benson, Yi Jen Chen, Michael A. Choti, Raza A. Dilawari, Charles Arthur Enke, Marwan G. Fakih, Charles Fuchs, Krystyna Kiel, James A. Knol, Lucille A. Leong, Kirk A. Ludwig, Edward W. Martin, Sujata Rao, M. Wasif Saif, Leonard Saltz, John M. Skibber, Alan P. Venook, Timothy J. Yeatman

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

The NCCN Colon/Rectal/Anal Cancer Guidelines panel believes that a multidisciplinary approach is necessary for managing colorectal cancer. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for resectable colon cancer is an en bloc resection. For patients with stage 111 disease, 5-FU-based adjuvant therapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. Surgery should be followed by adjuvant chemotherapy. The panel advocates a conservative posttreatment surveillance program for colon carcinoma patients. Serial CEA determinations are appropriate if the patient is a candidate for aggressive surgical resection, should recurrence he detected. Abdominal and pelvic CT scans should be used only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be treated with combination chemotherapy consisting of 5-FU/leucovorin and either irinotecan or oxaliplatin.

Original languageEnglish (US)
Pages (from-to)468-491
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number4
StatePublished - Jul 1 2005

Fingerprint

Practice Guidelines
Colonic Neoplasms
Fluorouracil
oxaliplatin
irinotecan
Colon
Anus Neoplasms
Recurrence
Leucovorin
Adjuvant Chemotherapy
Rectal Neoplasms
Combination Drug Therapy
Lung Diseases
Liver Diseases
Colorectal Neoplasms
Therapeutics
Clinical Trials
Guidelines
Carcinoma
Survival

Keywords

  • 5-fluorouracil
  • Adenocarcinoma
  • Adjuvant chemotherapy
  • Colonic neoplasms
  • Colorectal surgery
  • Irinotecan
  • NCCN clinical practice guidelines
  • Neoplasm recurrence
  • Neoplasm staging
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology

Cite this

Engstrom, P. F., Benson, A. B., Chen, Y. J., Choti, M. A., Dilawari, R. A., Enke, C. A., ... Yeatman, T. J. (2005). Colon cancer clinical practice guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 3(4), 468-491.

Colon cancer clinical practice guidelines. / Engstrom, Paul F.; Benson, Al B.; Chen, Yi Jen; Choti, Michael A.; Dilawari, Raza A.; Enke, Charles Arthur; Fakih, Marwan G.; Fuchs, Charles; Kiel, Krystyna; Knol, James A.; Leong, Lucille A.; Ludwig, Kirk A.; Martin, Edward W.; Rao, Sujata; Saif, M. Wasif; Saltz, Leonard; Skibber, John M.; Venook, Alan P.; Yeatman, Timothy J.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 3, No. 4, 01.07.2005, p. 468-491.

Research output: Contribution to journalReview article

Engstrom, PF, Benson, AB, Chen, YJ, Choti, MA, Dilawari, RA, Enke, CA, Fakih, MG, Fuchs, C, Kiel, K, Knol, JA, Leong, LA, Ludwig, KA, Martin, EW, Rao, S, Saif, MW, Saltz, L, Skibber, JM, Venook, AP & Yeatman, TJ 2005, 'Colon cancer clinical practice guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 3, no. 4, pp. 468-491.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA et al. Colon cancer clinical practice guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 2005 Jul 1;3(4):468-491.
Engstrom, Paul F. ; Benson, Al B. ; Chen, Yi Jen ; Choti, Michael A. ; Dilawari, Raza A. ; Enke, Charles Arthur ; Fakih, Marwan G. ; Fuchs, Charles ; Kiel, Krystyna ; Knol, James A. ; Leong, Lucille A. ; Ludwig, Kirk A. ; Martin, Edward W. ; Rao, Sujata ; Saif, M. Wasif ; Saltz, Leonard ; Skibber, John M. ; Venook, Alan P. ; Yeatman, Timothy J. / Colon cancer clinical practice guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2005 ; Vol. 3, No. 4. pp. 468-491.
@article{fbf7f4ebceda471386538e18582355ca,
title = "Colon cancer clinical practice guidelines",
abstract = "The NCCN Colon/Rectal/Anal Cancer Guidelines panel believes that a multidisciplinary approach is necessary for managing colorectal cancer. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for resectable colon cancer is an en bloc resection. For patients with stage 111 disease, 5-FU-based adjuvant therapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. Surgery should be followed by adjuvant chemotherapy. The panel advocates a conservative posttreatment surveillance program for colon carcinoma patients. Serial CEA determinations are appropriate if the patient is a candidate for aggressive surgical resection, should recurrence he detected. Abdominal and pelvic CT scans should be used only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be treated with combination chemotherapy consisting of 5-FU/leucovorin and either irinotecan or oxaliplatin.",
keywords = "5-fluorouracil, Adenocarcinoma, Adjuvant chemotherapy, Colonic neoplasms, Colorectal surgery, Irinotecan, NCCN clinical practice guidelines, Neoplasm recurrence, Neoplasm staging, Oxaliplatin",
author = "Engstrom, {Paul F.} and Benson, {Al B.} and Chen, {Yi Jen} and Choti, {Michael A.} and Dilawari, {Raza A.} and Enke, {Charles Arthur} and Fakih, {Marwan G.} and Charles Fuchs and Krystyna Kiel and Knol, {James A.} and Leong, {Lucille A.} and Ludwig, {Kirk A.} and Martin, {Edward W.} and Sujata Rao and Saif, {M. Wasif} and Leonard Saltz and Skibber, {John M.} and Venook, {Alan P.} and Yeatman, {Timothy J.}",
year = "2005",
month = "7",
day = "1",
language = "English (US)",
volume = "3",
pages = "468--491",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Colon cancer clinical practice guidelines

AU - Engstrom, Paul F.

AU - Benson, Al B.

AU - Chen, Yi Jen

AU - Choti, Michael A.

AU - Dilawari, Raza A.

AU - Enke, Charles Arthur

AU - Fakih, Marwan G.

AU - Fuchs, Charles

AU - Kiel, Krystyna

AU - Knol, James A.

AU - Leong, Lucille A.

AU - Ludwig, Kirk A.

AU - Martin, Edward W.

AU - Rao, Sujata

AU - Saif, M. Wasif

AU - Saltz, Leonard

AU - Skibber, John M.

AU - Venook, Alan P.

AU - Yeatman, Timothy J.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - The NCCN Colon/Rectal/Anal Cancer Guidelines panel believes that a multidisciplinary approach is necessary for managing colorectal cancer. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for resectable colon cancer is an en bloc resection. For patients with stage 111 disease, 5-FU-based adjuvant therapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. Surgery should be followed by adjuvant chemotherapy. The panel advocates a conservative posttreatment surveillance program for colon carcinoma patients. Serial CEA determinations are appropriate if the patient is a candidate for aggressive surgical resection, should recurrence he detected. Abdominal and pelvic CT scans should be used only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be treated with combination chemotherapy consisting of 5-FU/leucovorin and either irinotecan or oxaliplatin.

AB - The NCCN Colon/Rectal/Anal Cancer Guidelines panel believes that a multidisciplinary approach is necessary for managing colorectal cancer. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for resectable colon cancer is an en bloc resection. For patients with stage 111 disease, 5-FU-based adjuvant therapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. Surgery should be followed by adjuvant chemotherapy. The panel advocates a conservative posttreatment surveillance program for colon carcinoma patients. Serial CEA determinations are appropriate if the patient is a candidate for aggressive surgical resection, should recurrence he detected. Abdominal and pelvic CT scans should be used only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be treated with combination chemotherapy consisting of 5-FU/leucovorin and either irinotecan or oxaliplatin.

KW - 5-fluorouracil

KW - Adenocarcinoma

KW - Adjuvant chemotherapy

KW - Colonic neoplasms

KW - Colorectal surgery

KW - Irinotecan

KW - NCCN clinical practice guidelines

KW - Neoplasm recurrence

KW - Neoplasm staging

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=27744586750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744586750&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 468

EP - 491

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 4

ER -